Gross Margin % is calculated as gross profit divided by its revenue. Supernus Pharmaceuticals's Gross Profit for the
three
months ended in Dec. 2023 was $144.7 Mil. Supernus Pharmaceuticals's Revenue for the
three
months ended in Dec. 2023 was $164.3 Mil. Therefore, Supernus Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 was 88.06%.
Warning Sign:
Supernus Pharmaceuticals Inc gross margin has been in long-term decline. The average rate of decline per year is -2.5%.
The historical rank and industry rank for Supernus Pharmaceuticals's Gross Margin % or its related term are showing as below:
SUPN'
s Gross Margin % Range Over the Past 10 Years
Min: 86.21 Med: 94.04 Max: 96.24
Current: 86.21
During the past 13 years, the highestGross Margin % of Supernus Pharmaceuticals was 96.24%. The lowest was 86.21%. And the median was 94.04%.
SUPN's Gross Margin % is ranked better than 95.76% of 990
companies
in the Drug Manufacturers industry
Industry Median: 46.765
vs SUPN: 86.21
Supernus Pharmaceuticals had a gross margin of 88.06% for the quarter that ended in Dec. 2023 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Supernus Pharmaceuticals was -2.50% per year.
Supernus Pharmaceuticals Gross Margin % Historical Data
The historical data trend for Supernus Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Supernus Pharmaceuticals's Gross Margin %
For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supernus Pharmaceuticals's Gross Margin % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Supernus Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Supernus Pharmaceuticals had a gross margin of 88.06% for the quarter that ended in Dec. 2023 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Supernus Pharmaceuticals Gross Margin % Related Terms
Thank you for viewing the detailed overview of Supernus Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Supernus Pharmaceuticals (Supernus Pharmaceuticals) Business Description
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SUPN has been successfully added to your 